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Original Study
Association Between Vestibular Migraine and Migraine Headache:
Yet to Explore
yMehdi Abouzari, Khodayar Goshtasbi, Omid Moshtaghi, Donald Tan,
Harrison W. Lin, and zHamid R. Djalilian
Department of Otolaryngology–Head and Neck Surgery, University of California, Irvine; yDivision of Pediatric Otolaryngology,
Children’s Hospital of Orange County, Orange; and zDepartment of Biomedical Engineering, University of California,
Irvine, California
Objectives: To evaluate if patients with a diagnosis of
vestibular migraine (VM) by the International Classification
of Headache Disorders (ICHD) criteria have meaningful
differences in symptomatology and disease characteristics
when compared to patients with concurrent vestibular
symptoms and migraine that do not meet ICHD criteria.
Methods: Patients who presented for the evaluation of
vertigo were provided a detailed questionnaire about dizzi-
ness and migraine symptoms. Patients were assigned to
either VM cohort (met ICHD criteria for VM) or migraine
headache (MH) cohort (met ICHD criteria for migraine with
or without aura but not VM). Disease characteristics,
symptomatology, quality of life, and perceived stress score
were compared between the cohorts.
Results: The VM cohort demonstrated a shorter duration of
vertigo episodes, 11 22 hours versus 84 146 hours in the
MH cohort. In the VM cohort, 81% reported experiencing
migraine headaches during episodes of vertigo, versus 61%
in the MH cohort. All patients in the VM cohort reported a
previous diagnosis of migraine headache, whereas 9% of the
MH cohort had not been previously diagnosed by another
physician. There was no difference in quality of life or
perceived stress scores between the cohorts.
Conclusions: A large proportion of vertigo patients with
migrainous features do not meet the ICHD criteria for VM.
The differences between cohorts represent selection bias
rather than meaningful features unique to the cohorts. As
such, VM and MH with vestibular symptoms may exist on a
spectrum of the same disease process and may warrant the
same treatment protocols. Key Words: Dizziness—ICHD
criteria—Migraine headache—Vertigo—Vestibular migraine.
Otol Neurotol 41:392–396, 2020.
Vestibular migraine (VM) is a clinical diagnosis made
for certain patients who suffer from both migraine and
vestibular vertigo as defined by strict criteria outlined in
the International Classification of Headache Disorders
(ICHD), 3rd edition (1,2). VM is the second most com-
mon cause of recurrent vertigo, and has been found to
represent 6 to 7% of patients in dizziness clinics and in
9% of patients in a migraine clinic cohort (3–5). In VM,
migraine is the causative factor for the patient’s recurrent
episodes of vertigo and its treatment is targeted toward
the underlying disorder (6). Interestingly, the discovery
of VM was not based on a proposed pathophysiological
mechanism, but rather the statistical observation by
Neuhauser et al. (7) that migraine headache and vestibu-
lar vertigo exist concurrently three times more often than
would be expected by chance.
The literature has used various additional terms to
describe the population of patients who experience over-
lapping features of both migraine headache (MH) and
vestibular vertigo. These include migrainous vertigo,
migraine-associated vertigo, migraine-associated dizzi-
ness, migraine-related vestibulopathy, and benign recur-
rent vertigo (3). However, little is known about these
patients who are suspected of, but do not strictly meet the
criteria for VM. Since the establishment of the ICHD
criteria, there has been concern in the literature that these
patients might benefit from VM treatment but may be
excluded by the strict criteria. For instance, significant
symptomatic improvement in dizziness has been docu-
mented with migraine treatments in these patients in a
number of studies (5,8–11). However, as these studies
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predate the ICHD 3rd edition, a number of study partic-
ipants would not meet current criteria for VM despite
improvement with therapy. In this article, we aim to
assess whether the application of current ICHD criteria
results in a significant delineation in characteristics of
patients who do or do not meet criteria for VM.
METHODS
Following Institutional Review Board approval, patients who
presented with a chief complaint of at least 1 month of vertigo or
disequilibrium to our tertiary care academic center’s neuro-
tology clinic from 2014 to 2018 were screened for inclusion in
our study. At the initial visit, each patient was asked to complete
a detailed questionnaire about their symptoms in addition to
standard care. These patients were specifically evaluated for
meeting the ICHD 3rd edition beta criteria for VM and migraine
with or without aura, as shown in supplemental digital content
1, http://links.lww.com/MAO/A909 (1). The entire cohort
included patients if they had each of the following: history
of migraine headache based on the ICHD criteria, chronic or
episodic vertigo lasting longer than 1 month, and a subjective
description of their symptoms as a ‘‘room spinning’’ sensation.
The cohort was then subdivided into a VM cohort (those who
met ICHD criteria for VM) and an MH cohort (those who did
not meet criteria for VM but met criteria for migraine with or
without aura).
The detailed characterization of subjective migraine and
vertigo symptoms such as onset, frequency, triggers, associated
symptoms, etc. was compared between the two cohorts. Addi-
tionally, all subjects were queried about stress and quality of life
impairment related to vertigo over the preceding 2 months. The
quality of life instrument was modified from the Kato et al.
Menie`re’s disease outcomes questionnaire that consists of one
global quality-of-life question as well as questions in three
domains of physical, emotional, and social well-being (12).
Stress was measured using the perceived stress scale, a Likert-
type scale with 10 questions and scores ranging from 0 to 40
(13). Statistical analysis was performed using PASW Statistics
18.0 software (SPSS Inc., Chicago, IL) with a p value of less
than 0.05 considered to be statistically significant. Due to the
large number of analyzed variables and to avoid reporting of
false significant results, secondary Bonferroni correction via
dividing this significance threshold by the number of variables
(n¼ 38) yielding a significance threshold of p¼ 0.001 was
considered. Chi-square or Fisher’s exact test, and independent
samples t test were used to compare categorical and numerical
variables between the two cohorts, respectively.
RESULTS
A total of 427 patients were screened for inclusion in
the study and asked to fill out the questionnaires. Of
those, 396 responders completed the surveys satisfacto-
rily. Based on those surveys, 104 patients were assigned
to the VM cohort, 100 patients were assigned to the MH
cohort, and 192 patients did not meet the criteria for
either cohort. The average age of all patients was 53 years
(range: 14–81 yr). There was no statistically significant
difference in sex or age between the VM (68% females,
age 49 16 yr) and MH (70% females, age 53 14 yr)
cohorts ( p¼ 0.95 and p¼ 0.28, respectively). Most MH
patients did not meet VM criteria for two primary
reasons: 1) 63% of MH patients did not report at least
half of their vertiginous episodes associated with
migrainous features, and 2) 40% of MH patients reported
vestibular symptoms did not last between 5 minutes and
72 hours (57% less than 5 min and 43% greater than 72 h).
Additionally, within the MH cohort, 91 (91%) patients
met the criteria for migraine with aura and only 9 (9%)
patients suffered from migraine without aura.
Two features of vertigo symptomatology showed a
significant difference between the VM and MH cohorts
(Table 1). The VM cohort demonstrated a shorter average
duration of vertigo episodes, 11 22 hours versus
84 146 hours in the MH cohort ( p¼ 0.01). Moreover,
the VM cohort contained a greater proportion of patients
who reported having migraine headache concurrently
with episodes of vertigo, 81% versus 61% ( p¼ 0.01).
As shown in Table 2, all patients in the VM cohort had a
TABLE 1. Vertigo characteristics, symptoms, and triggers of the population cohort
VM (n¼ 104) MH (n¼ 100) p Value
Vertigo characteristics
Years since onset of first episode 7 9 6 10 0.831
Age at onset of first episode 41 16 48 16 0.082
No. of episodes per day 1.7 4 3 5 0.435
Duration of episodes (hours) 11 22 84 146 0.010
Concurrent migraine headache during episodes 89 (86%) 61 (61%) 0.010
Vertigo symptoms and triggers
Positional vertigo 91 (88%) 83 (83%) 0.680
Rotational vertigo 80 (77%) 65 (65%) 0.301
Vertigo triggered by visual motion 81 (78%) 72 (72%) 0.641
Concurrent cochlear symptoms
Ear pressure 68 (65%) 54 (54%) 0.641
Tinnitus 71 (68%) 59 (59%) 0.435
Hearing loss 44 (42%) 37 (37%) 0.880
Table entries are mean  standard deviation or total (percentage).
MH indicates migraine headache; VM: vestibular migraine. P values computed using independent samples t test and chi-square/Fisher’s exact
tests for numerical and categorical variables, respectively. Asterisk denotes a significant p value.
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previous diagnosis of migraine disorder, whereas only
91% of the MH cohort had been previously diagnosed
( p¼ 0.01). Though significant on primary analysis, Bon-
ferroni correction deemed these three variables nonsig-
nificant. There was no significant difference in scores on
any of the four quality of life domains or on perceived
stress scale between the two cohorts (Table 3).
DISCUSSION
We found that patients who fulfill the ICHD criteria for
VM are very similar in characteristics from vertigo
patients with a history of migraine headache who do
not fulfill the VM criteria. With few exceptions, nearly
every qualitative metric used to describe the two cohorts
failed to show a statistically significant difference. Even
the three significant variables on primary analysis would
be considered nonsignificant upon correction for poten-
tial multiple-testing error. Notably, the triggers and type
of vertigo symptoms described were similarly prevalent
in both cohorts. Because VM is a clinical diagnosis, the
significant symptomatic overlap between MH and VM
suggests etiological similarities between the two condi-
tions. In our study, we found that adhering strictly to the
ICHD criteria would miss a nearly equivalent population
of patients with migraine headaches and vertigo whose
TABLE 2. Migraine characteristics, symptoms, and triggers of population cohort
VM (n¼ 104) MH (n¼ 100) p Value
Migraine characteristics
Years since onset of first headache 13 14 16 16 0.407
Age at onset of first headache 36 16 36 18 1.00
No. of headaches per week 4 9 3 6 0.761
Family history of migraine 27 (26%) 35 (35%) 0.435
Past history of migraine 104 (100%) 91 (91%) 0.010
Past history of sinus headache 57 (55%) 66 (66%) 0.359
Symptoms associated with migraine headache
Pulsation or throbbing pain 61 (59%) 59 (59%) 0.880
Unilateral head pain 80 (77%) 69 (69%) 0.944
Allodynia 20 (19%) 28 (28%) 0.350
Visual symptoms 42 (40%) 39 (39%) 1.00
Weakness 48 (46%) 51 (51%) 0.646
Difficulty speaking 28 (27%) 23 (23%) 0.880
Nausea 61 (59%) 50 (50%) 0.649
Light sensitivity 77 (74%) 65 (65%) 0.642
Sound sensitivity 75 (72%) 63 (63%) 0.642
Drowsiness 53 (51%) 45 (45%) 0.813
Lightheadedness 69 (66%) 54 (54%) 0.407
Migraine triggers
Menstruation 48 (46%) 39 (39%) 0.873
Certain foods 20 (19%) 27 (27%) 0.350
Sleep disturbances 64 (62%) 51 (51%) 0.795
Physical activity 38 (37%) 33 (33%) 0.873
Bowel movements 16 (15%) 14 (14%) 1.00
Table entries are mean  standard deviation or total (percentage).
MH indicates migraine headache; VM, vestibular migraine, P values computed using independent samples t test and chi-square/Fisher’s exact
tests for numerical and categorical variables, respectively. Asterisk denotes a significant p value.
TABLE 3. Comparison of quality of life domains and perceived stress scale scores between the two cohorts.
VM (n¼ 104) MH (n¼ 100) p Value
Quality of life
Global domain 2.4 1 2.9 1 0.182
Mental domain 3 1 3.1 0.9 0.641
Physical domain 2.9 0.8 2.9 0.7 0.873
Social domain 3 1 2.9 0.6 0.171
Perceived stress scale 19 8 16 8 0.407
Table entries are mean  standard deviation.
MH indicates migraine headache; VM, vestibular migraine. P values computed using independent samples t test.
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vertigo might possibly respond just as well to migraine
treatment.
Current ICHD criteria require that at least half of
vertiginous episodes be associated with migrainous fea-
tures (migraine headache, photo/phonophobia, or aura).
An important finding that distinguished our cohorts was
that a greater proportion of VM patients had experienced
a migraine headache concurrently during episodes of
vertigo. This finding is consistent with recent studies
using ICHD criteria that report nearly all VM patients
experience VM and migraine concurrently (14,15). How-
ever, previous studies using less strict criteria for VM
have reported a lower co-occurrence of migraine and
vertigo of 24 to 45% (4,7,16–18). This suggests our
finding is likely a result of the classification of the disease
rather than an intrinsic feature.
Thirty-nine percent of our MH cohort had not experi-
enced vertigo and migraine headache concurrently.
These patients pose a clinical challenge, as they are more
likely to be excluded from a diagnosis of VM. However,
it is unclear whether their underlying disease process and
potential to respond to treatment are truly distinct from
patients who meet criteria for VM. There is concern in the
literature that these patients represent underdiagnosis of
VM (5,19–21). In other words, the current ICHD criteria
may be causing underdiagnosis of VM through exclusion
of patients who experience vertigo and migraine head-
ache separately. Another significant difference between
our cohorts was the average duration of vertigo episodes.
This indicates that the duration of symptoms was a key
factor in the diagnosis and subsequent assignment to each
cohort. ICHD criteria require that episodes last between 5
minutes and 72 hours. In our cohort of 100 patients with
MH, 40% did not meet ICHD criteria of VM due to the
duration of vertigo. This is potentially problematic as the
duration criteria have changed over time and clinically
may be difficult to estimate accurately (22).
In characterizing vertigo duration in VM, other authors
have previously used a variety of time frames. Had we
applied Neuhauser criteria instead of ICHD, 18% of our
VM cohort would have experienced vertigo lasting less
than 5 minutes (4). In a study by Zhang et al. that assessed
VM according to ICHD, the authors chose to exclude the
duration criterion when clinicians thought it was appro-
priate (14). These criteria are meant to exclude other
etiologies of brief or long-lasting vertigo such as benign
paroxysmal positional vertigo, vestibular neuritis, or
labyrinthitis. Previous reports in the literature and our
findings show that the duration criteria play a significant
role in excluding patients from the diagnosis of VM.
Two different mechanisms of action can explain the
duration of vertigo caused by migraine. Cutrer and Baloh
(23) proposed that short duration vertigo spanning
minutes to hours may result from the same mechanism
of cortical depression observed in migraine with aura and
longer lasting episodes beyond 24 hours can be caused by
neuroactive peptides. Furthermore, vertigo symptoms
lasting beyond 72 hours may have a similar pathophysi-
ology to status migrainosus. In status migrainosus,
patients experience a migraine headache lasting more
than 72 hours (24). Those experiencing vertigo during the
same time frame could also be suffering from an episode
of status migrainosus manifesting as vertigo symptoms.
Thus, arguments can be made that limiting a VM diag-
nosis to vertigo lasting within a 5-minute and 72-hour
time window excludes many patients possibly suffering
from VM. Furthermore, it is important to consider the
reliability of patient-reported symptom duration. Patients
could be experiencing true vertigo lasting between 5
minutes and 72 hours but feel unsteady for days and
weeks after. This could lead patients to mistakenly state
the duration of feeling ‘‘dizzy’’ or imbalanced rather than
of true vertigo. This creates a challenge for clinicians as
the criteria are strict and specific while their patient’s
report may be markedly less-so. To overcome this prob-
lem, we specifically asked patients for the duration of
their vertigo episode.
In our study, only a fraction of our patients suspected
of VM met ICHD criteria. When ICHD criteria are
applied retrospectively to published studies describing
VM, 30 to 50% of patients do not meet criteria for VM as
well (4,7,25,26). In a time before 2013 when ICHD
criteria did not include a diagnosis of VM, Neuhauser
developed criteria that continued to evolve and be modi-
fied throughout the decade. Future updates to ICHD
criteria should consider expanding the definition of
VM or the formal addition of a probable VM diagnosis.
These actions would have important clinical significance
as patients who are underdiagnosed are also most
likely undertreated.
The patient population described is a highly selective
population at a tertiary academic intuition with a suspi-
cion for VM, which represents significant selection bias.
Furthermore, this study did not include a control cohort.
A cohort suffering from vertigo without any migraine
features would have served as a reference cohort to
provide more evidence in support of the findings in
our study. One statistical consideration was the presence
of a large number of analyzed variables, where a signifi-
cance threshold of 0.05 for analyzing 38 variables could
lead to an 86% chance of at least one false significant
result. As such, Bonferroni correction was discussed to
control for this potential statistical error, which did not
drastically change the theme of this manuscript consid-
ering its explorative nature. Future directions include
larger scale prospective and randomized clinical studies
of these patients’ response to migraine therapy to not only
further define this population but to also provide clues of
the most effective means of diagnosis and treatment.
CONCLUSION
Our findings demonstrate that a large proportion of
vertigo patients with migrainous features do not meet the
ICHD criteria for VM. In comparing VM and MH
cohorts, we found remarkable similarity in the overlap
of their symptomatology. The differences between
cohorts were best explained as a result of diagnostic
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criteria rather than intrinsic features unique to the
cohorts. As such, VM and MH may exist on a spectrum
of the same disease process and therefore warrant the
same treatment protocols.
REFERENCES
1. Headache Classification Committee of the International Headache
Society (IHS). The International Classification of Headache Dis-
orders, 3rd edition (beta version). Cephalalgia 2013;33:629–808.
2. Headache Classification Committee of the International Headache
Society (IHS). The International Classification of Headache Dis-
orders, 3rd edition. Cephalalgia 2018;38:1–211.
3. Neuhauser HK. The epidemiology of dizziness and vertigo. Handb
Clin Neurol 2016;137:67–82.
4. Neuhauser H, Leopold M, Von Brevern M, Arnold G, Lempert T.
The interrelations of migraine, vertigo, and migrainous vertigo.
Neurology 2001;56:436–41.
5. Dieterich M, Brandt T. Episodic vertigo related to migraine (90
cases): Vestibular migraine? J Neurol 1999;246:883–92.
6. Neuhauser H, Lempert T. Vestibular migraine. Neurol Clin
2009;27:379–91.
7. Neuhauser HK, Radtke A, Von Brevern M, et al. Migrainous
vertigo: Prevalence and impact on quality of life. Neurology
2006;67:1028–33.
8. Bikhazi P, Jackson C, Ruckenstein MJ. Efficacy of antimigrainous
therapy in the treatment of migraine-associated dizziness.Am J Otol
1997;18:350–4.
9. Johnson GD. Medical management of migraine-related dizziness
and vertigo. Laryngoscope 1998;108:1–28.
10. Waterston J. Chronic migrainous vertigo. J Clin Neurosci
2004;11:384–8.
11. Whitney SL, Wrisley DM, Brown KE, Furman JM. Physical therapy
for migraine-related vestibulopathy and vestibular dysfunction with
history of migraine. Laryngoscope 2000;110:1528–34.
12. Kato BM, LaRouere MJ, Bojrab DI, Michaelides EM. Evaluating
quality of life after endolymphatic sac surgery: The Me´nie`re’s
Disease Outcomes Questionnaire. Otol Neurotol 2004;25:339–44.
13. Cohen S, Kamarck T, Mermelstein R. A global measure of per-
ceived stress. J Health Soc Behav 1983;24:385–96.
14. Zhang Y, Kong Q, Chen J, Li L, Wang D, Zhou J. International
Classification of Headache Disorders 3rd edition beta-based field
testing of vestibular migraine in China: Demographic, clinical
characteristics, audiometric findings and diagnosis statues. Ceph-
alalgia 2016;36:240–8.
15. Cho SJ, Kim BK, Kim BS, et al. Vestibular migraine in multicenter
neurology clinics according to the appendix criteria in the third beta
edition of the International Classification of Headache Disorders.
Cephalalgia 2016;36:454–62.
16. Kayan A, Hood JD. Neuro-otological manifestations of migraine.
Brain 1984;107:1123–42.
17. Von Brevern M, Radtke A, Clarke AH, Lempert T. Migrainous
vertigo presenting as episodic positional vertigo. Neurology
2004;62:469–72.
18. Vukovic´ V, Plavec D, Galinovic´ I, Lovrencˇic´-Huzjan A, Budisˇic´ M,
Demarin V. Prevalence of vertigo, dizziness, and migrainous
vertigo in patients with migraine. Headache 2007;47:1427–35.
19. Brandt T, Dieterich M. The vestibular cortex: Its locations, func-
tions, and disorders. Ann N Y Acad Sci 1999;871:293–312.
20. Brandt T, Strupp M. Migraine and vertigo: Classification, clinical
features and special treatment considerations. Headache Curr
2006;3:12–9.
21. Brandt T, Dieterich M, Strupp M. Vertigo and Dizziness, 2nd ed.
London, UK: Springer-Verlag; 2013.
22. Lempert T, Olesen J, Furman J, et al. Vestibular migraine: Diag-
nostic criteria. J Vestib Res 2012;22:167–72.
23. Cutrer FM, Baloh RW. Migraine associated dizziness. Headache
1992;32:300–4.
24. Solomon S. Migraine diagnosis and clinical symptomatology.
Headache 1994;34:S8–12.
25. Radtke A, Neuhauser H, Von Brevern M, Hottenrott T, Lempert T.
Vestibular migraine-validity of clinical diagnostic criteria. Cepha-
lalgia 2011;31:906–13.
26. Radtke A, Von Brevern M, Neuhauser H, Hottenrott T, Lempert
T. Vestibular migraine; Long-term follow-up of clinical
symptoms and vestibulo-cochlear findings. Neurology 2012;79:
1607–14.
396 M. ABOUZARI ET AL.
Otology & Neurotology, Vol. 41, No. 3, 2020
